A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (AEB1102)
An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A
Sponsor: Aeglea Biotherapeutics
This PHASE2 trial investigates Arginase I Deficiency and Hyperargininemia and is currently completed. Aeglea Biotherapeutics leads this study, which shows 17 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
17 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE2
▶ Show 12 earlier versions
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE2
-
Dec 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Jun 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Jul 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aeglea Biotherapeutics
For direct contact, visit the study record on ClinicalTrials.gov .